ArticleJournal of neuro-oncology2025
Diffuse pontine glioma (DPG): shorter or longer treatment time?
Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeDiffuse intrinsic pontine glioma is a lethal disease with a median overall survival (OS) of less than one year. Currently, no curative treatment exists, and radiotherapy primarily aims for symptom palliation. Hypofractionated radiotherapy (HR) has been proposed to enhance quality of life through shorter treatment duration, fewer hospital visits, and reduced costs, particularly in low- and middle-income countries (LMICs). However, many LMIC institutions continue to use 54 Gy in 30 fractions. The study aims to identify patients who may benefit from HR.
methodsWe reviewed data from MAHAK patients treated between April 2010 and February 2020. Diagnosis was based on clinical symptoms and MRI imaging; biopsy was not mandatory.
resultsAmong 108 identified patients, 34(32%) underwent a biopsy, with high-grade glioma or glioblastoma diagnosed in 18(53%). H3K27M mutation was found in two patients, while others were not evaluated. No seeding was detected at diagnosis. Thirty-one patients (29%) received 50-54 Gy using normal fractionation, while the remainder received HR. Median OS was 9.6 months (range 1-67). No significant impact of fractionation was observed. Seventy-eight (72%) patients received chemotherapy, which showed no benefit. Eleven patients received re-irradiation at progression, showing a post-progression OS of 6 months. Poor-risk factors included age over 4 years, symptom duration < 3months, simultaneous triad signs, and absence of hydrocephalus (p < 0.05).
conclusionGiven their shorter life expectancy, poor-risk patients may benefit from HR. We propose a scoring system based on prognostic factors to guide decisions between HR and normal fractionation.
Indexed as
Identifiers
41134453What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.